Companies / ATH

ALTERITY THERAPEUTICS LIMITED

ASX:ATHPharmaceuticals, Biotechnology & Life SciencesSuspended from quotation
217.7M shares on issueAppendix 2A · as of 28 July 2026$0.56price · delayed$121.9Mmarket cap · indicative
NR
Dilution grade

Not rated — the company is suspended from quotation

Cash runwayno data — suspended — grade not computed
Share-count growth (24m)no data — suspended — grade not computed
Raise cadence (24m)0 cash raises
Options & rights overhangno dataconsolidation-adjusted
In-the-money supplyno data — no recent share price on record
Pending proposed issuesnone

ALTERITY THERAPEUTICS LIMITED's latest ordinary share count, adjusted for the April 2026 consolidation (approximately 1-for-1.7), stands at 218M shares as of July 2026. The company raised capital eight times in the 24-month window for disclosed proceeds totalling A$122.1M, most recently a A$20.0M placement in September 2025. At the March 2026 quarter the company reported A$42.3M in cash. There are no proposed securities issues (Appendix 3B) pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
659.3%
Max option dilution
534.0%
ITM option dilution
2
Raises · last 12 months
8.9 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-1.7 consolidation (30 Apr 2026). Latest count 217.7M per Appendix 2A (28 July 2026).
217.53M217.57M217.60MJune 26July 26July 26

Cash runway

8.9 qtrs
More than four quarters of funding at the recent spend rate.
$42.3M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
28 July 20262A · quoted issueATH : ORDINARY FULLY PAID217.7MAppendix 2A
21 July 20262A · quoted issueATH : ORDINARY FULLY PAID217.6MAppendix 2A
9 July 20262A · quoted issueATH : ORDINARY FULLY PAID217.6MAppendix 2A
1 July 20262A · quoted issueATH : ORDINARY FULLY PAID217.5MAppendix 2A
15 June 20263H · cancellationATH : ORDINARY FULLY PAID217.5MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

8 cash raises in the last 24 months · 2 in the last 12 months

$20.0M
Placement
3 Sept 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

consolidation-adjusted Figures rebased for the share consolidation in the last 24 months.

659.3%
Total overhang · of current shares
534.0%
In the money · at current price
1.44B
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
15 June 2026Julian BarbaczyOther—2.0M—3Y notice
15 June 2026Lawrence GozlanOther121k1.0M—3Y notice
6 Jan 2026David StamlerSell—91—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026Application for quotation of securities - ATH
21 July 2026Alterity to Participate in the BTIG Biotechnology Conference
21 July 2026Application for quotation of securities - ATH
9 July 2026$PATH Receives A$3.98m R&D Tax Incentive
9 July 2026Application for quotation of securities - ATH
6 July 2026$PFDA Meeting Minutes Confirm Registrational Path for ATH434
1 July 2026Application for quotation of securities - ATH
29 June 2026Change in substantial holding
17 June 2026Change of Director's Interest Notice x 2
16 June 2026Corporate Presentation June 2026
15 June 2026Notification regarding unquoted securities - ATH
15 June 2026Notification of cessation of securities - ATH
12 June 2026Completion of Consolidation
29 May 2026Results of Meeting
19 May 2026Alterity Data Supports ATH434 Phase 3 Advancement in MSA
12 May 2026Corporate Presentation May 2026
10 May 2026Alterity Announces Publication on MRI as Biomarker for MSA
7 May 2026Alterity to Deliver Presentations at May Medical Meetings
30 Apr 2026Consolidation/Split - ATH
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.